AU5548801A - Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies - Google Patents

Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies

Info

Publication number
AU5548801A
AU5548801A AU5548801A AU5548801A AU5548801A AU 5548801 A AU5548801 A AU 5548801A AU 5548801 A AU5548801 A AU 5548801A AU 5548801 A AU5548801 A AU 5548801A AU 5548801 A AU5548801 A AU 5548801A
Authority
AU
Australia
Prior art keywords
retinoid receptor
receptor antagonists
agonists
cartilage
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU5548801A
Other languages
English (en)
Inventor
Maurizio Pacifici
Roshantha A Chandraratna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Publication of AU5548801A publication Critical patent/AU5548801A/xx
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AU5548801A 2000-04-20 2001-04-19 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies Pending AU5548801A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/552,823 US20030114482A1 (en) 1999-12-15 2000-04-20 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
PCT/US2001/012742 WO2001080894A2 (en) 2000-04-20 2001-04-19 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies

Publications (1)

Publication Number Publication Date
AU5548801A true AU5548801A (en) 2001-11-07

Family

ID=24206947

Family Applications (3)

Application Number Title Priority Date Filing Date
AU5548801A Pending AU5548801A (en) 2000-04-20 2001-04-19 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
AU2001255488A Ceased AU2001255488B2 (en) 2000-04-20 2001-04-19 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
AU2006233216A Abandoned AU2006233216A1 (en) 2000-04-20 2006-10-27 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2001255488A Ceased AU2001255488B2 (en) 2000-04-20 2001-04-19 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
AU2006233216A Abandoned AU2006233216A1 (en) 2000-04-20 2006-10-27 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies

Country Status (9)

Country Link
US (1) US20030114482A1 (https=)
EP (1) EP1274456B1 (https=)
JP (1) JP2003531180A (https=)
AT (1) ATE285794T1 (https=)
AU (3) AU5548801A (https=)
CA (1) CA2407021A1 (https=)
DE (1) DE60108094T2 (https=)
HK (1) HK1053053B (https=)
WO (1) WO2001080894A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007518719A (ja) * 2003-12-26 2007-07-12 アラーガン　インコーポレイテッド ＲＡＲγレチノイド受容体アンタゴニスト活性を有する二置換カルコンオキシム
JP2007070281A (ja) * 2005-09-06 2007-03-22 Matsumoto Shika Univ レチノイドｘ受容体関連化合物を用いた骨粗鬆症の治療剤
EP1959945B1 (en) * 2005-12-13 2014-12-03 McGill University Fenretinide for correcting a lipid imbalance in a subject
US20090209601A1 (en) * 2008-02-15 2009-08-20 Wyeth Use of rxr agonists for the treatment of osteoarthritis
EP3721880B1 (en) 2010-09-01 2022-02-02 Thomas Jefferson University Composition and method for muscle repair and regeneration
US20140094512A1 (en) * 2012-10-02 2014-04-03 Nikolas Gunkel Method of modulating the degree of adipose tissue deposited intramuscularly
US9492431B2 (en) 2012-11-08 2016-11-15 Yamaguchi University Therapeutic agent for keratoconjunctive disorders
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
ES2694831T3 (es) 2013-05-22 2018-12-27 Yamaguchi University Inhibidor para trastornos retinocoroideos
JP7023868B2 (ja) 2016-06-08 2022-02-22 クレメンティア ファーマシューティカルズ，インコーポレイテッド 異所性骨化を治療するための方法
CA3043807A1 (en) 2016-11-16 2018-05-24 Clementia Pharmaceuticals Inc. Methods for treating multiple osteochondroma (mo)
AU2018300150A1 (en) 2017-07-11 2020-01-30 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US5977125A (en) * 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
US5514825A (en) * 1994-12-29 1996-05-07 Allergan, Inc. Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5648514A (en) * 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
DE19501032A1 (de) * 1995-01-14 1996-07-18 Max Delbrueck Centrum Mittel zur Behandlung von rheumatischen Erkrankungen
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5877207A (en) * 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
CN1255396C (zh) * 1996-03-18 2006-05-10 卫材株式会社 含有稠环的羧酸衍生物
US5808124A (en) * 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5773594A (en) * 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5763635A (en) * 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5760276A (en) * 1997-03-06 1998-06-02 Allergan Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
US5962707A (en) * 1998-08-18 1999-10-05 Wisconsin Alumni Research Foundation 19-nor-vitamin D3 compounds with calcemic activity
CA2254429A1 (en) * 1998-11-19 2000-05-19 Tully Michael Underhill Compositions for promoting chondrogenesis
DE19910246A1 (de) * 1999-03-08 2000-09-28 Bayer Ag Trennfreundliche Polyurethan-Formschaum-Systeme
CA2402413A1 (en) * 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis

Also Published As

Publication number Publication date
WO2001080894A2 (en) 2001-11-01
AU2001255488B2 (en) 2006-07-27
ATE285794T1 (de) 2005-01-15
DE60108094D1 (de) 2005-02-03
EP1274456A2 (en) 2003-01-15
JP2003531180A (ja) 2003-10-21
HK1053053B (en) 2005-06-10
DE60108094T2 (de) 2005-12-15
AU2006233216A1 (en) 2006-11-16
HK1053053A1 (en) 2003-10-10
WO2001080894A3 (en) 2002-07-25
EP1274456B1 (en) 2004-12-29
CA2407021A1 (en) 2001-11-01
US20030114482A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
WO2001043732A3 (en) Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
SG148037A1 (en) Fgf variants and methods for use thereof
AU5548801A (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
EA200100642A1 (ru) Получение и применение радия-223 для направленной доставки к кальцифицированным тканям в целях временного ослабления боли, терапии рака кости и кондиционирования костной поверхности
DE60120372D1 (de) Verwendung von insulin zur behandlung von knorpelkrankheiten
IL147271A0 (en) Compounds that bind her2
DE60018048D1 (de) Vorrichtung zur fixierung von osteoporotischen knochen
DE602004011394D1 (en) Thiazolderivate
AP9801269A0 (en) Prostaglandin agonists.
PT2009025E (pt) Método de inibição da actividade dos osteoclastos
EA200100184A1 (ru) Новые гидратные формы алендроната натрия, способы их получения и фармацевтические композиции
AU7096201A (en) Phospholipid derivatives of valproic acid and mixtures thereof
YU13301A (sh) Muskarinski agonisti i antagonisti
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
TR200200278T2 (tr) Kalsilitik bileşimler
GB2331301B (en) Galanin
MXPA03004547A (es) Agonistas receptores de d4 de dopamina selectivos para el tratamiento de disfuncion sexual.
AU2003251729A8 (en) Use of antibodies against flt-1 for the treatment of osteoporosis
MX9800801A (es) Proteina mp52 arg humana.
PT1165184E (pt) Antagonismo do receptor-beta do estrogenio e doencas de ossos
MY138502A (en) Novel alkansulfonamides as endothelin antagonists
EP0904094A4 (en) TREATMENT OF BONE DISEASES WITH ADRENOMEDULLIN
PT1301192E (pt) Utilização de ciclodextrinas polissulfatadas para o tratamento de artrose